What Is Citrobacter Koseri? Infections, Symptoms & Causes

Citrobacter koseri is a gram-negative bacterium belonging to the Enterobacteriaceae family, best known for causing devastating brain abscesses in newborns and opportunistic infections in people with weakened immune systems. It lives naturally in the human gut and in the environment, and most healthy adults will never have a problem with it. But for vulnerable populations, particularly neonates in the first two months of life, it ranks among the most dangerous bacterial pathogens that can invade the central nervous system.

A Common Gut Bacterium With an Uncommon Reputation

Citrobacter species are rod-shaped, non-spore-forming bacteria that thrive in a range of environments: soil, sewage, water, food, and the intestinal tracts of both humans and animals.¹ Within this genus, C. koseri occupies a specific niche. It has gone by several names over the years, including Citrobacter diversus and Levinea malonatica, all of which refer to the same organism.² If you come across older medical literature referring to C. diversus, it is talking about C. koseri under its previous name.³

The bacterium is classified as an opportunistic pathogen, meaning it typically does not cause disease in healthy individuals. It waits for an opening: a compromised immune system, an extremely young host, or an underlying medical condition. The most common sites of infection in adults are the urinary tract, the gastrointestinal system, and the respiratory tract, while in newborns it targets the bloodstream and the membranes surrounding the brain.⁴

Who Is at Risk

Three groups bear the highest burden of C. koseri infection: newborns (especially premature infants), elderly patients, and immunocompromised individuals.⁴ In otherwise healthy adults, invasive C. koseri infections are rare enough that individual cases get written up in medical journals. One published case involved a 30-year-old man with no prior health issues who developed a serious heart valve infection caused by C. koseri, an event surprising enough that it prompted a report describing it as one of the few documented cases in a patient with a fully functional immune system.⁵

For immunocompromised adults, risk factors include conditions like diabetes, chronic kidney disease, cancer, HIV, or the use of immunosuppressive medications. Structural abnormalities in the urinary tract also raise the risk. One case report described a patient with spina bifida and an ileal conduit who developed a C. koseri urinary tract infection that escalated into an abscess around the kidney and eventually spread to the chest cavity.⁶ These complications are atypical for a standard urinary tract infection, which underscores how C. koseri can become aggressive in the right host.

The Notorious Danger to Newborns

What sets C. koseri apart from most other bacteria in its family is its extraordinary tendency to cause brain abscesses in neonates. During the first two months of life, the bacterium shows a strong predilection for the central nervous system, and when it causes meningitis in this age group, it frequently progresses to multiple brain abscesses.⁷ This is not a minor complication. The mortality rate for C. koseri meningitis in newborns is around 30%, and among infants who survive, more than 80% are left with some degree of lasting neurological damage.⁷ Long-term outcomes can include seizures, intellectual disability, and partial paralysis.⁸

The symptoms of neonatal C. koseri meningitis include poor feeding, vomiting, lethargy, episodes where the baby stops breathing briefly, seizures, irritability, and a bulging soft spot on the skull. A tricky aspect of brain abscesses in infants is that some babies initially show no obvious neurological symptoms beyond increased fussiness, which can delay diagnosis.⁷ By the time the abscess is identified on imaging, significant damage may already have occurred.

How C. Koseri Hijacks the Immune System

The mechanism behind C. koseri’s ability to establish brain abscesses is genuinely unusual among bacteria, and it helps explain why neonatal infections are so difficult to treat. Research using neonatal rat models has shown that C. koseri does not simply float through the bloodstream and lodge in brain tissue. Instead, the bacterium gets swallowed by macrophages, the immune cells that are supposed to kill invaders, and then survives and multiplies inside them.⁹

Normally, when a macrophage engulfs a bacterium, it fuses the compartment containing the microbe with digestive sacs called lysosomes, which break the invader down with enzymes and acidic conditions. C. koseri survives this process. More than 90% of the bacteria inside macrophages were found to be sitting within these merged digestive compartments, alive and replicating.⁹ The bacteria essentially use the immune cells as a hiding place and a vehicle, being carried into the central nervous system while shielded from both the immune response and from antibiotics circulating in the blood.

As these infected macrophages accumulate in the brain, the dead tissue and the mass of immune cells trying to contain the infection form the abscess itself. Some of these abscesses lack the fibrous capsule that typically walls off a brain abscess, making them harder to contain and treat surgically.⁷ The brain’s own immune cells, called microglia, also take up C. koseri and may serve as yet another reservoir for the pathogen during central nervous system infections.¹⁰

How the Infection Spreads

C. koseri reaches its human hosts through several routes. Newborns can acquire the bacterium through vertical transmission from the mother during pregnancy or birth, or through horizontal transmission in hospital settings. In many neonatal cases, the original source is never identified.¹¹

Mother-to-child transmission has been confirmed using molecular fingerprinting techniques. In one documented case, a pregnant woman with an infected placental membrane and bloodstream infection passed C. koseri to her infant, who was born already in septic shock. Researchers used two independent DNA-typing methods to prove that the mother’s strain and the baby’s strain were genetically identical, confirming a direct maternal source.¹²

In adults, infections generally arise from the patient’s own gut flora, particularly when a medical device like a urinary catheter is present, or when a surgical procedure breaches normal barriers. Hospital-acquired transmission between patients is also possible, especially in intensive care units where colonized patients can spread the organism to others through shared equipment or healthcare workers’ hands.

Adult Infections Beyond the Urinary Tract

While urinary tract infections are the most common manifestation in adults, C. koseri can cause a surprisingly wide range of infections when given the opportunity. Reported cases include pneumonia, bloodstream infections, wound infections, and abdominal abscesses. Bone infections are another rare but documented complication. A case report described a young, otherwise healthy man who developed osteomyelitis (bone infection) caused by C. koseri, which was unusual enough to be noteworthy precisely because the patient had no immune deficiency.⁴

C. koseri has also been implicated in adverse pregnancy outcomes. A published case documented second-trimester fetal loss linked to C. koseri infection that caused premature rupture of the membranes.¹¹ Veterinary researchers have similarly isolated the bacterium from aborted fetal tissues in cattle, suggesting it can cause reproductive infections across species.¹³

Antibiotic Resistance and Why It Matters

C. koseri carries a chromosomal gene that produces a low-level beta-lactamase enzyme called CKO. This enzyme is produced constitutively, meaning the bacterium makes it all the time rather than ramping up production in response to antibiotic exposure.¹⁴ On its own, this built-in beta-lactamase provides modest resistance to some older penicillins but does not typically interfere with treatment using modern antibiotics like third-generation cephalosporins or carbapenems.

The bigger concern is acquired resistance. A study from Japan found that roughly a third of clinical C. koseri isolates produced extended-spectrum beta-lactamases, enzymes that break down a much broader range of antibiotics, including the cephalosporins commonly used as first-line therapy. In some regions of southern Japan, that figure reached 60%.¹⁵ These are worrying numbers because they mean standard empiric antibiotic choices may fail before culture results come back.

Even more alarming is the emergence of carbapenem-resistant C. koseri. Carbapenems are often considered last-resort antibiotics for serious gram-negative infections, and resistance to them dramatically limits treatment options. A recent study from long-term care hospitals found C. koseri was the dominant Citrobacter species in both clinical and surveillance specimens, and the most common resistance mechanism was a gene called KPC, found in over three-quarters of clinical isolates.¹⁶ Long-term care facilities, with their high antibiotic use and vulnerable patient populations, appear to be a particular hotspot for these resistant strains.

How C. Koseri Infections Are Treated

Treatment depends on the site and severity of the infection, but all C. koseri infections require antibiotic therapy guided by the specific sensitivity profile of the isolate.¹⁷ The antibiotic classes that have historically been used include aminoglycosides, cephalosporins, carbapenems, chloramphenicol, and fluoroquinolones.¹⁷

For uncomplicated urinary tract infections in adults, treatment is relatively straightforward, and outcomes are generally good with appropriate antibiotics. Central nervous system infections in neonates, however, represent a far more difficult clinical challenge. Traditional therapy with third-generation cephalosporins and aminoglycosides has not prevented the high rates of death and disability associated with neonatal C. koseri meningitis. One analysis argued that a key reason for poor outcomes is that conventional antibiotics do not reach adequate concentrations inside the immune cells where C. koseri hides, or within the central nervous system itself. Based on their ability to penetrate both macrophages and the brain, ciprofloxacin and meropenem have been proposed as the most appropriate options for serious systemic and central nervous system C. koseri infections.¹⁸

When brain abscesses develop, surgical drainage is often required alongside antibiotic therapy. Even with aggressive combined medical and surgical treatment, outcomes in neonatal cases remain poor. About half of surviving infants are left with significant neurological problems, including seizures, developmental delay, and weakness or paralysis on one side of the body.⁸

Diagnosing C. Koseri

In most clinical settings, C. koseri is identified through standard blood or body fluid cultures followed by biochemical testing or automated identification systems. One challenge historically has been that C. koseri and the closely related species Citrobacter amalonaticus look very similar in standard biochemical tests, which has led to misidentification. Genetic analysis of the beta-lactamase genes carried by each species has been proposed as a way to tell them apart more reliably.³

Modern technology has made identification faster and more accurate. Newer methods like microarray-based assays and mass spectrometry can identify gram-negative bacteria directly from blood culture bottles with very high accuracy. One study evaluating a panel designed to detect gram-negative organisms in blood cultures reported concordance rates above 99% for identifying targeted bacteria, including Citrobacter species.¹⁹ Speed matters here, especially in neonatal cases where every hour of delay in appropriate antibiotic treatment worsens outcomes.

C. Koseri in Animals and the Environment

C. koseri is not exclusively a human pathogen. The bacterium exists naturally in the digestive tracts of animals and has been isolated from a variety of environmental sources.¹ In veterinary medicine, it has been linked to reproductive disease in cattle. Researchers in Japan isolated C. koseri from the liver, spleen, kidney, heart, lung, brain, and skeletal muscle of aborted bovine fetuses, as well as from the fetal membranes, demonstrating that the organism can cause systemic fetal infection and pregnancy loss across species.¹³

This environmental and animal reservoir means that C. koseri is essentially impossible to eradicate. The practical focus for preventing human disease falls on infection control in hospitals, particularly in neonatal intensive care units where outbreaks can occur through horizontal transmission between patients. Screening, cohorting of colonized infants, rigorous hand hygiene, and antibiotic stewardship remain the primary tools for limiting spread in these settings. For adults outside of healthcare facilities, the risk of a clinically significant C. koseri infection remains very low as long as the immune system is functioning normally.

1
PubMed Central. A brief insight into Citrobacter species – a growing threat to public health
2
PubMed Central. Citrobacter koseri. I. An extended antigenic scheme for Citrobacter koseri
3
PubMed. Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology
4
PubMed Central. Osteomyelitis Caused by Citrobacter koseri in a Young Immunocompetent Man
5
PubMed Central. Infective endocarditis due to Citrobacter koseri in an immunocompetent adult
6
PubMed Central. Urinary Tract Infection Caused by Citrobacter koseri in a Patient With Spina Bifida, an Ileal Conduit and Renal Calculi Progressing to Peri-nephric Abscess and Empyema
7
PubMed Central. Favorable outcome in cerebral abscesses caused by Citrobacter koseri in a newborn infant
8
PubMed. Long-Term outcome of neonatal Citrobacter koseri (diversus) meningitis treated with imipenem/meropenem and surgical drainage
9
PubMed Central. Citrobacter koseri brain abscess in the neonatal rat: survival and replication within human and rat macrophages
10
PubMed Central. Microglial activation by Citrobacter koseri is mediated by TLR4- and MyD88-dependent pathways
11
PubMed Central. Second Trimester Fetal Loss Due to Citrobacter koseri Infection: A Rare Cause of Preterm Premature Rupture of Membranes (PPROM)
12
PubMed. Transmission of Citrobacter koseri from mother to infant documented by ribotyping and pulsed-field gel electrophoresis
13
PubMed Central. Citrobacter koseri related abortion and fetal septicemia in cattle
14
PubMed. Characterization of the chromosomal class A beta-lactamase CKO from Citrobacter koseri
15
PubMed. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2
16
Korean Journal of Healthcare-Associated Infection Control and Prevention. Carbapenem-Resistant Citrobacter koseri: An Emerging Concern in Long-term Care Hospital
17
PubMed. Optimum management of Citrobacter koseri infection
18
PubMed. Treatment of Citrobacter koseri infection with ciprofloxacin and cefotaxime in a preterm infant
19
American Journal of Clinical Pathology. Microarray-Based Nucleic Acid Assay and MALDI-TOF MS Analysis for the Detection of Gram-Negative Bacteria in Direct Blood Cultures